PR Newswire BiotechOriginal article
PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
Data ReadoutpositivePMB-CT01Positive
AI Analysis
Summary
PeproMene Bio announced Phase 1 trial results for PMB-CT01 published in The Lancet, demonstrating deep and durable complete responses in recurrent or refractory B-cell lymphomas, including in patients who failed CD19-targeted CAR-T cell therapy.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Phase 1 trial demonstrated deep and durable complete responses in recurrent or refractory B-cell lymphomas, including patients who failed CD19-targeted CAR-T cell therapy
Importance:7/10
Sentiment:
0.85
phase_1_datapublicationcell_therapylymphomaCAR-Tclinical_trial
Read the original article
Published by PR Newswire Biotech on September 8, 2026 10:01 AM